Dr Berdeja on the Current Role of BCMA-Targeted Therapies in Multiple Myeloma
November 8th 2023Jesus Berdeja, MD, discusses the current role of BCMA-targeted therapies in multiple myeloma, and imparts advice to colleagues regarding the sequencing of bispecific antibodies and CAR T-cell therapies.
Read More
Dr Berdeja on Ongoing and Planned Research Initiatives in Patients With Multiple Myeloma
October 26th 2023Jesus Berdeja, MD, director, discusses ongoing and planned research initiatives in patients with multiple myeloma, specifically highlighting initiatives taking place at Tennessee Oncology.
Read More